Logo image of QLGN

QUALIGEN THERAPEUTICS INC (QLGN) Stock Fundamental Analysis

NASDAQ:QLGN - Nasdaq - US74754R3012 - Common Stock - Currency: USD

3.53  -0.16 (-4.34%)

Fundamental Rating

0

Taking everything into account, QLGN scores 0 out of 10 in our fundamental rating. QLGN was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of QLGN have multiple concerns. QLGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QLGN has reported negative net income.
In the past year QLGN has reported a negative cash flow from operations.
QLGN had negative earnings in each of the past 5 years.
In the past 5 years QLGN always reported negative operating cash flow.
QLGN Yearly Net Income VS EBIT VS OCF VS FCFQLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

QLGN has a Return On Assets of -343.34%. This is amonst the worse of the industry: QLGN underperforms 93.91% of its industry peers.
Industry RankSector Rank
ROA -343.34%
ROE N/A
ROIC N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QLGN Yearly ROA, ROE, ROICQLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QLGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QLGN Yearly Profit, Operating, Gross MarginsQLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

QLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
QLGN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for QLGN has been increased compared to 5 years ago.
Compared to 1 year ago, QLGN has a worse debt to assets ratio.
QLGN Yearly Shares OutstandingQLGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
QLGN Yearly Total Debt VS Total AssetsQLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -83.83, we must say that QLGN is in the distress zone and has some risk of bankruptcy.
QLGN has a worse Altman-Z score (-83.83) than 95.34% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -83.83
ROIC/WACCN/A
WACC9.56%
QLGN Yearly LT Debt VS Equity VS FCFQLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.52 indicates that QLGN may have some problems paying its short term obligations.
QLGN's Current ratio of 0.52 is on the low side compared to the rest of the industry. QLGN is outperformed by 92.11% of its industry peers.
QLGN has a Quick Ratio of 0.52. This is a bad value and indicates that QLGN is not financially healthy enough and could expect problems in meeting its short term obligations.
QLGN has a worse Quick ratio (0.52) than 91.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.52
QLGN Yearly Current Assets VS Current LiabilitesQLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

QLGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1416.24%.
The Revenue for QLGN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1416.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-552.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, QLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 31.80% on average per year.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

QLGN Yearly Revenue VS EstimatesQLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 1M 2M 3M 4M 5M
QLGN Yearly EPS VS EstimatesQLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 -50K -100K -150K -200K -250K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLGN Price Earnings VS Forward Price EarningsQLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLGN Per share dataQLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40 -50

4.3 Compensation for Growth

QLGN's earnings are expected to grow with 31.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QLGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUALIGEN THERAPEUTICS INC

NASDAQ:QLGN (7/15/2025, 8:16:14 PM)

3.53

-0.16 (-4.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-14 2025-07-14
Earnings (Next)08-12 2025-08-12
Inst Owners1.17%
Inst Owner Change0%
Ins Owners0.09%
Ins Owner Change0%
Market Cap5.79M
Analysts82.86
Price TargetN/A
Short Float %1.69%
Short Ratio1.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-56.1
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-5.93
FCFYN/A
OCF(TTM)-5.93
OCFYN/A
SpS0
BVpS-1.31
TBVpS-1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -343.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.52
Altman-Z -83.83
F-Score2
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1416.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-552.28%
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.1%
OCF growth 3YN/A
OCF growth 5YN/A